Published in Digestion on January 01, 1980
Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology (2000) 5.34
Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med (1996) 3.47
Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut (2004) 3.01
Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut (2004) 2.29
Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther (1999) 2.26
Enhancement of the GDP-GTP exchange of RAS proteins by the carboxyl-terminal domain of SCD25. Science (1990) 2.24
Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet (1981) 2.02
Toward a model for the interaction between elongation factor Tu and the ribosome. Science (1993) 2.01
Kirromycin, an inhibitor of protein biosynthesis that acts on elongation factor Tu. Proc Natl Acad Sci U S A (1974) 1.97
Crystallization and properties of rabbit skeletal muscle phosphofructokinase. J Biol Chem (1966) 1.85
Expanded indications for ultrasound-guided thrombin injection of pseudoaneurysms. J Vasc Surg (2000) 1.77
Expression of the antiproliferative gene TIS21 at the onset of neurogenesis identifies single neuroepithelial cells that switch from proliferative to neuron-generating division. Proc Natl Acad Sci U S A (1999) 1.73
EEG features and epilepsy in patients with autism. Brain Dev (1995) 1.71
Enhanced mucosal interleukin-6 and -8 in Helicobacter pylori-positive dyspeptic patients. Am J Gastroenterol (1994) 1.69
Incidence of inflammatory bowel disease in Italy: a nationwide population-based study. Gruppo Italiano per lo Studio del Colon e del Retto (GISC) Int J Epidemiol (1996) 1.65
Mechanism of action of kirromycin-like antibiotics. Annu Rev Microbiol (1985) 1.65
Mechanism of the inhibition of protein synthesis by kirromycin. Role of elongation factor Tu and ribosomes. Eur J Biochem (1977) 1.63
Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis. Am J Pathol (1999) 1.62
Interaction of probiotic Lactobacillus and Bifidobacterium strains with human intestinal epithelial cells: adhesion properties, competition against enteropathogens and modulation of IL-8 production. Int J Food Microbiol (2008) 1.61
Steroid treatment in active Crohn's disease: a comparison between two regimens of different duration. Aliment Pharmacol Ther (1994) 1.59
Inhibition by siomycin and thiostrepton of both aminoacyl-tRNA and factor G binding to ribosomes. Proc Natl Acad Sci U S A (1971) 1.56
Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration. Kidney Int (2001) 1.51
Controlled study using wireless capsule endoscopy for the evaluation of the small intestine in chronic refractory pouchitis. Aliment Pharmacol Ther (2007) 1.49
Colonic motility and transit in health and ulcerative colitis. Gastroenterology (1991) 1.45
Reliability of the international spinal cord injury bowel function basic and extended data sets. Spinal Cord (2011) 1.45
Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study. Dig Liver Dis (2007) 1.43
Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. Am J Gastroenterol (2001) 1.43
Review article: the management of refractory Crohn's disease. Aliment Pharmacol Ther (2002) 1.41
Effect of kirromycin on elongation factor Tu. Location of the catalytic center for ribosome-elongation-factor-Tu GTPase activity on the elongation factor. Eur J Biochem (1977) 1.41
Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative? Gastroenterology (1999) 1.40
A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease. Gastroenterology (1986) 1.37
Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut (2006) 1.36
Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther (2006) 1.33
Properties and regulation of the GTPase activities of elongation factors Tu and G, and of initiation factor 2. Mol Cell Biochem (1981) 1.31
Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. Res Microbiol (2001) 1.29
Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig Dis Sci (1999) 1.29
Polyunsaturated fatty acids and inflammatory bowel disease. Am J Clin Nutr (2000) 1.27
EF-Tu, a GTPase odyssey. Biochim Biophys Acta (1998) 1.27
Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther (1999) 1.24
Participation in protein biosynthesis of transfer ribonucleic acids bearing altered 3'-terminal ribosyl residues. Biochemistry (1974) 1.23
Early-onset seizure variant of Rett syndrome: definition of the clinical diagnostic criteria. Brain Dev (2009) 1.23
Effects of the mutation glycine-222----aspartic acid on the functions of elongation factor Tu. Biochemistry (1987) 1.22
Elongation factor Tu resistant to kirromycin in an Escherichia coli mutant altered in both tuf genes. Proc Natl Acad Sci U S A (1977) 1.22
Band heterotopia: correlation of outcome with magnetic resonance imaging parameters. Ann Neurol (1994) 1.22
Association between postprandial changes in colonic intraluminal pressure and transit. Gastroenterology (1989) 1.21
[Epidemiological study on intestinal inflammatory diseases in the Province of Bologna]. G Clin Med (1977) 1.21
Modification of elongation-factor-Tu . guanine-nucleotide interaction by kirromycin. A comparison with the effect of aminoacyl-tRNA and elongation factor Ts. Eur J Biochem (1978) 1.16
Relapsing ulcerative colitis after spinal cord stimulation: a case of intestinal neurogenic inflammation? Gastroenterology (1999) 1.16
Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-alpha in ulcerative colitis. Am J Gastroenterol (1999) 1.16
Topical administration of 5-aminosalicylic acid enemas in patients with ulcerative colitis. Studies on rectal absorption and excretion. Gut (1985) 1.15
Effect of probiotic strains on interleukin 8 production by HT29/19A cells. Am J Gastroenterol (2002) 1.15
Familial perisylvian polymicrogyria: a new familial syndrome of cortical maldevelopment. Ann Neurol (2000) 1.13
Dietary habits as risk factors for inflammatory bowel disease. Eur J Gastroenterol Hepatol (1995) 1.12
Hearing loss in the Sjögren syndrome. Ann Intern Med (1997) 1.11
Prostaglandins, indomethacin, and ulcerative colitis. Gastroenterology (1980) 1.11
Relevance of histidine-84 in the elongation factor Tu GTPase activity and in poly(Phe) synthesis: its substitution by glutamine and alanine. FEBS Lett (1995) 1.11
Local injection of Infliximab for the treatment of perianal Crohn's disease. Dis Colon Rectum (2005) 1.09
New antibiotic that acts specifically on the GTP-bound form of elongation factor Tu. EMBO J (1991) 1.08
Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther (2002) 1.07
Mutations of Ha-ras p21 that define important regions for the molecular mechanism of the SDC25 C-domain, a guanine nucleotide dissociation stimulator. EMBO J (1992) 1.07
Isolation and characterization of two acidic proteins from the 50S subunit required for GTPase activities of both EF G and EF T. Biochem Biophys Res Commun (1972) 1.06
A comparative study of the 50S ribosomal subunit and several 50S subparticles in EF-T-and EF-G-dependent activities. Biochemistry (1975) 1.06
Hydrolysis of GTP by elongation factor Tu can be induced by monovalent cations in the absence of other effectors. J Biol Chem (1982) 1.05
Properties of a genetically engineered G domain of elongation factor Tu. Proc Natl Acad Sci U S A (1987) 1.05
Mucosal concentrations of interleukin-1 beta, interleukin-6, interleukin-8, and tumor necrosis factor-alpha in pelvic ileal pouches. Dig Dis Sci (1994) 1.05
Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. Clin Exp Immunol (2003) 1.04
Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. Aliment Pharmacol Ther (2002) 1.04
Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Aliment Pharmacol Ther (2009) 1.03
Rifaximin systemic absorption in patients with ulcerative colitis. Eur J Clin Pharmacol (1998) 1.03
Structure-function relationships in the GTP binding domain of EF-Tu: mutation of Val20, the residue homologous to position 12 in p21. EMBO J (1988) 1.03
Rectal cell proliferation and colon cancer risk in ulcerative colitis. Cancer Res (1990) 1.02
Epilepsy in adolescents and young adults with autistic disorder. Brain Dev (2000) 1.02
Changes in splanchnic hemodynamics in inflammatory bowel disease. Non-invasive assessment by Doppler ultrasound flowmetry. Scand J Gastroenterol (1992) 1.01
Crystalline transfer factors from Escherichia coli. Biochem Biophys Res Commun (1968) 1.00
Site-directed mutagenesis of elongation factor Tu. The functional and structural role of residue Cys81. Eur J Biochem (1992) 1.00